Want to see IN:GOCLCORP full AI Analyst Report?
Top Page
GOCL Corporation Limited
(GOCLCORP)
Select Model
Select Model
Rating:63Neutral
Price Target:
₹387.00
▼(-2.07% Downside)
Action:Reiterated
Date:09/08/26
The score is held back mainly by weak and inconsistent cash generation and highly volatile revenue/operating performance, despite a notably improved balance sheet. Offsetting this, the stock’s technical trend is strong and the valuation is compelling (low P/E with a dividend), supporting a mid-range overall rating.
Positive Factors
Materially stronger balance sheet
The substantial reduction in leverage lowers balance-sheet risk and can improve financial flexibility for operations, investment, or shareholder returns. Meaningful equity growth further strengthens the company’s ability to absorb volatility, although the speed of the capital-structure change warrants monitoring.
Negative Factors
Severe revenue volatility
A sharp latest-period revenue contraction makes near-term earnings power difficult to underwrite and suggests that operating scale is not stable. Persistent top-line volatility can weaken planning, reduce fixed-cost absorption, and make future profitability more dependent on uneven project or asset activity.
Read all positive and negative factors
Positive Factors
Negative Factors
Materially stronger balance sheet
The substantial reduction in leverage lowers balance-sheet risk and can improve financial flexibility for operations, investment, or shareholder returns. Meaningful equity growth further strengthens the company’s ability to absorb volatility, although the speed of the capital-structure change warrants monitoring.
Read all positive factors
GOCL Corporation Limited (GOCLCORP) vs. iShares MSCI India ETF (INDA)
Market Cap
₹18.00B
Dividend Yield8.26%
Average Volume (3M)30.59K
Price to Earnings (P/E)5.3
Beta (1Y)1.41
Revenue Growth-97.40%
EPS Growth-74.70%
CountryIN
Employees218
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)68.55
Shares Outstanding49,572,740
10 Day Avg. Volume31,688
30 Day Avg. Volume30,585
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.43
Price to Sales (P/S)137.00
P/FCF Ratio11.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
GOCL Corporation Limited Business Overview & Revenue Model
Company Description
GOCL Corporation Limited, established in 1961 and headquartered in Hyderabad, India, is a diversified enterprise with operations spanning India and international markets. The company primarily operates across three key segments: energetics, explos...
How the Company Makes Money
GOCLCORP makes money primarily through (1) the sale of industrial explosives and related products and (2) fees/revenue from associated services provided to industrial customers (such as support services linked to blasting operations and logistics/...
GOCL Corporation Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 106.56M | 97.63M | 5.55B | 6.10B | 9.21B | 4.98B |
| Gross Profit | 23.21M | 84.13M | 181.97M | 962.68M | 1.88B | 517.47M |
| EBITDA | 960.12M | 4.01B | 2.73B | 2.14B | 4.57B | 2.56B |
| Net Income | 3.40B | 15.22B | 1.57B | 482.53M | 2.11B | 1.76B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 35.55B | 31.09B | 29.00B | 35.04B | 32.43B |
| Cash, Cash Equivalents and Short-Term Investments | 939.61M | 939.61M | 998.49M | 845.75M | 1.03B | 475.41M |
| Total Debt | 0.00 | 6.15M | 11.15B | 11.88B | 17.67B | 15.95B |
| Total Liabilities | -31.43B | 4.12B | 15.32B | 14.81B | 20.95B | 20.92B |
| Stockholders Equity | 31.43B | 31.43B | 15.76B | 14.19B | 14.10B | 11.52B |
Cash Flow | ||||||
| Free Cash Flow | -262.25M | 1.12B | 9.30M | 244.13M | -961.54M | -726.28M |
| Operating Cash Flow | -220.22M | 1.33B | 156.72M | 400.03M | -766.37M | -617.13M |
| Investing Cash Flow | 9.81B | 8.64B | 2.22B | 7.34B | 1.73B | -3.22B |
| Financing Cash Flow | -9.65B | -9.94B | -2.30B | -8.00B | -898.46M | 3.87B |
GOCL Corporation Limited Technical Analysis
Negative
395.20
Price Trends
385.15
Negative
370.87
Negative
315.41
Positive
Market Momentum
-0.61
Positive
38.03
Neutral
5.13
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GOCLCORP, the sentiment is Negative. The current price of 395.2 is below the 20-day moving average (MA) of 396.99, above the 50-day MA of 385.15, and above the 200-day MA of 315.41, indicating a neutral trend. The MACD of -0.61 indicates Positive momentum. The RSI at 38.03 is Neutral, neither overbought nor oversold. The STOCH value of 5.13 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:GOCLCORP.
GOCL Corporation Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | ₹18.00B | 5.30 | ― | 8.26% | -97.40% | -74.70% | |
63 Neutral | ₹69.25B | 33.85 | ― | 0.52% | 11.08% | 34.10% | |
62 Neutral | ₹35.36B | 0.56 | ― | 0.10% | 10.71% | 2756.39% | |
60 Neutral | ₹42.29B | 82.22 | ― | 0.11% | 41.09% | 618.16% | |
57 Neutral | ₹23.69B | 15.71 | ― | 0.12% | 19.47% | 11.49% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
42 Neutral | ₹17.91B | 358.35 | ― | 0.47% | 8.40% | ― |
* General Sector Average
IN:GOCLCORP
GOCL Corporation Limited
363.05
27.46
8.18%
IN:BALAMINES
Balaji Amines Limited
2,137.40
741.66
53.14%
IN:CAMLINFINE
Camlin Fine Sciences Limited
93.25
-97.30
-51.06%
IN:KIRIINDUS
Kiri Industries Limited
542.55
-24.05
-4.24%
IN:ROSSARI
Rossari Biotech Ltd
427.65
-207.99
-32.72%
IN:TATVA
Tatva Chintan Pharma Chem Limited
1,807.90
781.88
76.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.